The Panadea ZIKV IgG ELISA Kit is based on the patented IgG FcγR ELISA technology. Samples are co-incubated togetherwith a horseradish peroxidase (HRP)-labeled recombinant ZIKV antigen and unlabeled protein competitors, suppressingcross-reactivity of other flaviviral infections in a microwell plate coated with a recombinant IgG immune complex specificcapture molecule.
During the incubation, IgG antibodies in the sample, the ZIKV antigens, and the competitor molecules form immunecomplexes, which then bind specifically and with high affinity to the capture molecules. All antibodies not binding to theantigen or the competitors, as well as any excess labeled antigen and competitors, are removed in the subsequentwashing step.
The bound IgG/antigen immune complexes are visualized by application of the colorimetric HRP substrate tetramethylben-zidine (TMB). After stopping the enzymatic reaction, the assay result is generated by measuring the optical density (OD) ofthe solution in the well at 450/620 nm.
Anzinger et al. (2022), Antenatal Seroprevalence of Zika and Chikungunya Viruses, Kingston Metropolitan Area, Jamaica,2017-2019. Emerg Infect Dis. 28(2):473-475
Ehmen et al. (2021), Accurate detection of Zika virus IgG using a novel immune complex binding ELISA.Trop Med Int Health 26(1):89-101